Seer, Inc. (SEER): PESTLE Analysis [Nov-2025 Updated]

You're running a deep proteomics company like Seer, Inc., which means you're operating in a high-stakes, volatile environment. The macro picture for 2025 is a classic growth-vs-risk trade-off: your core Proteograph technology is getting validated, but the money to buy it is getting tighter. Seer's full-year 2025 revenue is projected to hit the $17 million to $18 million range, showing solid growth, but that's a modest number against a Q3 net loss of $18.2 million. The challenge isn't the science; it's navigating the external forces-from shifting NIH funding and global supply chain risk to the relentless AI/ML innovation curve and the talent wars in the Boston/San Francisco hubs. We need to look past the strong balance sheet, which still holds approximately $251 million in cash, and defintely map the six critical macro-environmental factors that will determine if the platform can truly break through.

Seer, Inc. (SEER) - PESTLE Analysis: Political factors

Shifting US National Institutes of Health (NIH) funding priorities for proteomics research

The US government's allocation of research dollars through the National Institutes of Health (NIH) is a major political lever for a company like Seer, Inc. (SEER). The good news is that proteomics-the large-scale study of proteins-is defintely a growth area for federal grants. The total NIH program level request for the Fiscal Year (FY) 2025 budget was approximately $50.1 billion, and while that is a massive pool, the internal allocations matter more.

We see a clear trend of increased support for advanced proteomics capabilities within major research institutions. For instance, one NIH-funded Biopolymers & Proteomics core resource requested an 18.5% budget increase for its proteomics expertise in FY 2025, signaling a focus shift toward next-generation protein analysis. This directly benefits Seer, whose Proteograph™ Product Suite is designed to handle the complex, large-scale data that this new wave of funding is enabling. Plus, the NIH's 2025-2030 Strategic Plan for Data Science is pushing for greater data integration, which is critical for the massive datasets Seer's technology generates.

Geopolitical tensions impacting the global supply chain for specialized reagents and chips

Geopolitical friction is no longer just a macro-economic risk; it's a direct operational threat to life science supply chains, especially for high-tech instruments and consumables. Seer relies on specialized reagents and chips for its Proteograph platform, and these components are vulnerable to the US-China and broader global trade disputes. The US administration imposed new tariffs in 2025, and while pharmaceuticals initially saw exemptions, high-performance medical devices and lab equipment did not.

The impact is concrete: tariffs on key industrial metals like copper, aluminum, and stainless steel-all used in manufacturing complex instruments-were raised, with some reaching 50%. This directly increases the cost of goods sold (COGS) for Seer's instruments, which could squeeze the gross margin, reported at 51% in Q3 2025. Any disruption to the supply of specialized semiconductor chips, which are critical for the Proteograph's data processing, could stall instrument production and delay the delivery of the full-year 2025 revenue guidance of $17 million to $18 million.

Increased government focus on domestic biomanufacturing and life science independence

The US government is actively using political tools to onshore the life science industry, which presents both a risk and an opportunity for Seer. Executive Orders signed in May 2025 aim to accelerate the domestic manufacture of critical medicines and tighten the biosafety framework, which is a clear signal to the market.

This push is formalized through legislative efforts, like the bipartisan bill introduced in November 2025 to establish a National Biopharmaceutical Manufacturing Center of Excellence. This initiative is explicitly designed to reduce reliance on foreign supply chains, particularly China, and prioritizes federal procurement toward U.S.-based sources. For a US-based manufacturer like Seer, this creates a competitive advantage in securing government and academic contracts over foreign rivals, especially as the government increases scrutiny on foreign facilities.

• Opportunity: Prioritized access to US federal procurement contracts.
• Risk: Increased regulatory overhead from new biosafety and biorisk management plans.

Trade policies affecting the export of the Proteograph™ Product Suite to key Asian markets

Exporting the Proteograph™ Product Suite to key Asian markets is now a complex calculation, thanks to the new US reciprocal tariff framework implemented in 2025. This framework has created a tiered system of tariff exposure across Asia, directly impacting the cost and competitiveness of US-made equipment.

The Commerce Department also imposed new export controls in January 2025 on certain advanced biotechnology systems, citing national security concerns. While the Proteograph may not be explicitly named, its high-tech nature and use in AI-driven biological design tools make it vulnerable to future export license requirements for sales to 'countries of concern.'

Here is the quick math on the tariff exposure for key markets as of November 2025:

This tariff structure means Seer must focus its Asian sales efforts on lower-tariff corridor nations like Japan and South Korea, where the cost of the Proteograph remains competitive, while China sales become significantly more expensive for the end-user. The risk is that export controls could suddenly close off even these favorable markets.

Seer, Inc. (SEER) - PESTLE Analysis: Economic factors

Inflationary pressures increasing the cost of raw materials and R&D labor, squeezing margins.

You are defintely feeling the pinch of inflation in your supply chain and talent acquisition, and Seer, Inc. is no different. The cost of running an R&D-heavy business like Seer has risen across the board in 2025. For the broader US pharmaceutical sector, new tariffs introduced in April 2025 were estimated to represent a potential $20 billion annual cost increase industry-wide, which directly impacts the price of imported raw materials and reagents needed for the Proteograph platform's consumable kits.

This pressure is evident in the company's financials, even with cost-control efforts. While Seer's gross margin was a respectable 49% in Q1 2025 and 52% in Q2 2025, maintaining that margin requires constant vigilance against rising input costs. Plus, the ongoing requirement under US tax law (Section 174) to capitalize and amortize R&D expenses over five years-instead of deducting them immediately-puts a significant strain on cash flow for research-intensive companies like Seer, which often have a net loss.

Here's the quick math: Seer's R&D expenses for Q2 2025 were $12.0 million. Even though this was a 6% decrease from the prior year, the actual purchasing power of that budget is eroded by inflation and the tax capitalization rule, meaning the company must achieve more with less to hit its full-year revenue guidance of $17 million to $18 million. You have to be incredibly efficient just to tread water.

Volatility in venture capital and public market funding for biotech customers, slowing capital equipment purchases.

The biotech funding environment in 2025 has been a story of extreme selectivity, what we call a 'flight to quality.' After a strong start in Q1 2025, overall venture funding for biotech companies saw a sharp decline, falling from $7 billion to $4.8 billion in Q2 2025. This volatility directly impacts Seer because their customers-early-stage biotech firms, which are a key market for capital equipment like the Proteograph-are tightening their belts.

Investors are now prioritizing 'de-risked assets' and 'proven science,' which makes it harder for pre-clinical companies to secure the large, late-stage funding rounds needed to purchase high-value capital equipment. The good news is that the overall biotech market is projected to grow from $483 billion in 2024 to $546 billion in 2025, a 13% growth rate. But that growth is concentrated in areas like AI-driven drug discovery and gene therapy, forcing Seer to prove its platform is essential, not just a nice-to-have, for those high-growth segments.

The slowdown in funding means longer sales cycles for their instruments. That's a clear action item: focus your sales efforts on the well-funded, clinical-stage customers who have already passed the initial capital-raising hurdle.

Strong US Dollar (USD) potentially making the Proteograph platform more expensive for international buyers.

To be fair, the US Dollar (USD) story in 2025 is more about volatility than relentless strength, but the risk remains. While the Dollar Index (DXY) actually weakened by about 10.7% in the first half of 2025, making US exports temporarily cheaper and more competitive for international buyers, the currency has shown signs of rebounding in late 2025. A strong USD is a classic headwind for any US-based company selling high-value instruments overseas, as it directly increases the price in local currencies like the Euro or Yen.

What this estimate hides is the extreme sensitivity to policy uncertainty, which can cause rapid currency swings. If the USD stages a late-year rebound, as some forecasts suggest, it will immediately pressure international sales. This is a crucial factor for Seer as they expand their global footprint.

The currency fluctuation risk is compounded by the fact that the company's revenue is still relatively small, with full-year guidance at $17 million to $18 million. A sudden currency move can easily wipe out a significant portion of the margin on an international equipment sale.

Global GDP growth forecasts directly influencing academic and pharmaceutical research budgets.

The overall global economic picture for 2025 is one of deceleration, which directly impacts the budgets of Seer's key customers: academic institutions and large pharmaceutical companies. Global GDP growth is projected to slow from 3.3% in 2024 to 2.9% in 2025. More specifically, US GDP growth is forecast to decline from 2.8% in 2024 to 1.6% in 2025.

This slowdown translates to tighter government and institutional budgets. Seer has noted that its customers continue to face 'headwinds from budget constraints' and 'uncertainty around government funding,' particularly related to the National Institutes of Health (NIH). This is a material risk, considering that Seer expects approximately 30% of its overall 2025 revenue to come from academic and government entities.

Still, the long-term demand for the output of this research remains strong. Global medicine spending is projected to reach $1.6 trillion by 2025, with global pharmaceutical production and sales expected to grow by 3%. This suggests that while budget acquisition is harder, the underlying market for new drug discovery-which Seer's technology supports-is robust.

The table below summarizes the key economic drivers impacting Seer's operating environment in 2025:

Seer, Inc. (SEER) - PESTLE Analysis: Social factors

Growing public awareness and demand for personalized medicine and early disease detection

The societal shift toward proactive health management and personalized medicine (PM) is a powerful tailwind for Seer, Inc. You see this demand surge across the board, from consumer-facing health tech to major institutional investment in diagnostics. The global personalized medicine market size is a clear indicator of this momentum, projected to hit approximately US$654.46 billion in the 2025 fiscal year. This isn't a niche market anymore; it's a core component of future healthcare.

The push for early disease detection, where proteomics is critical, is a major driver. For instance, the oncology segment-a key application area for Seer's technology-accounts for an estimated 40.2% of the personalized medicine application market. People are actively seeking non-invasive ways to get real-time data about their bodies, which puts companies with advanced biomarker discovery platforms like Seer's Proteograph Product Suite in a prime position. This consumer and clinical demand is defintely pushing the market forward.

Here's the quick math on the specialized biomarker market, which directly impacts Seer's core business:

This growth rate is significantly higher than the broader personalized medicine market, underscoring the value placed on accurate, early-stage molecular diagnostics.

Talent wars in the Boston/San Francisco biotech hubs driving up compensation for specialized engineers and data scientists

The competition for specialized talent in the biotech hubs of Boston and San Francisco is fierce, and it directly impacts Seer's operating expenses. Your proteomics platform requires a rare mix of life science expertise and high-end data science skills to manage and interpret the massive multi-omics data sets. This combination creates a significant talent war, driving compensation for these specialized engineers sky-high.

Data science roles in the biotech/pharma sector are in such high demand that they stay open for a median of only 20 days, showing how quickly top talent is snapped up. For a company like Seer, which is headquartered in Redwood City, California, the cost of securing and retaining a skilled team is a constant pressure on the operating expenses, which were already $22.6 million in the second quarter of 2025.

To be fair, this talent is worth the investment, but you must be prepared to pay a premium. The market-driven compensation figures for a Biotech Data Scientist in these key hubs reflect this reality:

• Average annual pay in San Francisco, CA: $144,607.
• 90th percentile pay in San Francisco, CA: $203,823.
• Average annual pay in Boston, MA: $133,343.
• 90th percentile pay in Boston, MA: $187,947.

This salary inflation means your hiring budget needs to be robust, or you risk losing key computational biology and machine learning experts to larger pharma or tech companies.

Increased focus on health equity and access to advanced diagnostic tools in underserved populations

Health equity-ensuring everyone has a fair and just opportunity to attain their highest level of health-is moving from a moral concept to a business imperative in 2025. This focus is an opportunity and a risk for advanced diagnostic companies like Seer. You have a chance to expand your market into historically underserved populations, but you must address the access and affordability barriers.

The industry sentiment is clear: 75% of life sciences executives and 64% of health care executives expect an increased focus on health equity this year. Furthermore, 90% of leaders anticipate investment in these initiatives will either increase or remain steady. This societal pressure means that the utility of your Proteograph platform cannot be limited to well-funded academic labs; it must eventually translate into accessible clinical tools.

What this estimate hides is the execution challenge: 43% of life sciences executives report difficulty integrating health equity into their strategic and operational processes. Diagnostics are a key leverage point here, as they account for less than 5% of healthcare spending but influence nearly 70% of clinical decisions. If Seer can demonstrate a clear path for its technology to reduce disparities in early detection-for example, by enabling cheaper, high-throughput screening for diverse populations-it can tap into this growing investment pool and secure long-term market acceptance.

Academic and industry collaboration models evolving to accelerate biomarker discovery

The pace of biomarker discovery is accelerating, largely due to the evolution of academic and industry collaboration models. No single entity can handle the massive scale of multi-omics (layering data from genomics, proteomics, metabolomics, etc.) research required to find novel biomarkers. This is a positive social factor for Seer, as its technology is built for this type of large-scale, collaborative research.

The trend is moving toward standardized protocols and the use of real-world evidence (RWE) to validate new biomarkers, which requires deep partnerships. Seer is already participating in this model, which is a clear action point for the company's strategy:

• In June 2025, Seer launched a large-scale Proteograph study with Korea University.
• The study's goal is to identify blood biomarkers for early-onset cancers.
• It leverages Seer's Proteograph technology alongside artificial intelligence (AI) for analysis.

This partnership model is crucial because it helps translate the raw power of the Proteograph platform from a research tool into clinically relevant insights faster. By working with academic institutions, Seer ensures its technology is integrated into the next generation of biomarker science, which is increasingly focused on multi-omics and high-throughput profiling. This is how you accelerate discovery from the lab bench to a clinical impact.

Seer, Inc. (SEER) - PESTLE Analysis: Technological factors

Rapid advancements in Artificial Intelligence (AI) and Machine Learning (ML) for analyzing complex proteomic data sets.

The biggest technological opportunity for Seer, Inc. is the rapid acceleration of Artificial Intelligence (AI) and Machine Learning (ML) in data analysis. This isn't just a buzzword; it's the only way to process the sheer volume of data the Proteograph system generates. The global market for AI in Proteomics is projected to be valued at $1,404 million in 2025, and it's growing at a Compound Annual Growth Rate (CAGR) of 12.3% through 2035.

This growth confirms that the industry is relying on algorithms to find patterns in complex protein data that a human analyst simply cannot see. Seer is already leaning into this by partnering with institutions like Korea University on a landmark 20,000-sample population-scale study to develop AI-driven diagnostics for cancers. That's a clear action mapping a trend to a core business strategy. The ability to integrate AI/ML directly into the software component of the Proteograph Product Suite is what will defintely convert raw data into actionable clinical insights for researchers.

Competitive pressure from next-generation sequencing (NGS) platforms expanding into protein analysis.

You need to be a realist about the competition, and the pressure from Next-Generation Sequencing (NGS) platforms is real. While Seer focuses on deep, unbiased proteomics, major players in the genomics space, like Illumina, are constantly evolving their high-throughput platforms, such as the NovaSeq X, to offer unmatched speed and data output. The global protein sequencing market itself is forecasted to grow from $1.7 billion in 2024 to $1.88 billion in 2025, showing a CAGR of 10.5%. This convergence of 'omics' technologies means that the traditional lines between genomics and proteomics are blurring.

Companies like Thermo Fisher Scientific and QIAGEN, which dominate the broader bioinformatics market, offer comprehensive solutions that span both genetic and protein analysis. They have massive customer bases and robust data analysis ecosystems. The risk here is that an NGS giant could acquire or develop a complementary protein analysis technology that directly competes with the Proteograph at a similar scale or better price point, essentially forcing Seer to compete with a multi-billion dollar genomics machine.

Need to continuously innovate the Proteograph workflow to maintain its throughput advantage over competitors.

Innovation is not optional; it's the price of admission. Seer's core advantage is the scalability and depth of its Proteograph workflow, and the company knows it. That's why the launch of the new Proteograph ONE assay and SP200 Automation Instrument in May 2025 was a crucial move.

Here's the quick math on their innovation: the new workflow doubles throughput to over 1,000 samples weekly per SP200 instrument. Plus, the operational efficiencies have reduced the per-sample analysis cost by about 60% compared to the 2021 release. This kind of step-change improvement is necessary to stay ahead of the curve and justify the full-year 2025 revenue guidance of between $17 million and $18 million. The company must keep this pace of innovation to ensure its proprietary engineered nanoparticles and streamlined automation remain best-in-class.

Key Proteograph ONE Workflow Advancements (2025):

• Doubled throughput to over 1,000 samples weekly.
• Reduced per-sample analysis cost by approximately 60%.
• Achieved automated run time of under 5 hours for 80-sample batches.

Cybersecurity risks associated with managing large, sensitive customer proteomic data clouds.

As Seer's technology drives population-scale studies-like the 20,000-sample collaboration-the volume of sensitive customer proteomic data stored in the cloud explodes. This data, which is essentially the molecular blueprint of a person's health, is a prime target. The financial impact of a breach is staggering: the global average cost of a data breach has already increased to $4.88 million in 2024.

The cloud environment is the main vulnerability. About 45% of security incidents are reported to have originated from cloud environments, and over 60% of organizations experienced security incidents related to public cloud usage in 2024. For a life sciences company, this risk is compounded by the regulatory and ethical implications of losing patient-derived data. Misconfigurations in cloud settings, like poorly secured storage buckets, are the most common entry points for attackers. You can't afford to treat security as an afterthought when dealing with data this valuable.

Finance: Budget a 15% increase in cloud security spending for the next fiscal year, specifically targeting Identity and Access Management (IAM) and continuous monitoring tools.

Seer, Inc. (SEER) - PESTLE Analysis: Legal factors

Stricter regulatory pathways for in vitro diagnostics (IVD) in the US and Europe impacting time-to-market.

The regulatory landscape for in vitro diagnostics (IVD) is tightening significantly in 2025, directly impacting Seer, Inc.'s product commercialization timelines in key markets. In the European Union, the In Vitro Diagnostic Regulation (IVDR) transition is a major compliance hurdle. Manufacturers of high-risk Class D devices, which could include some advanced proteomic assays, were required to apply for a Notified Body assessment by May 26, 2025, to benefit from the extended transitional periods. Failure to meet this deadline means the device cannot be legally placed on the EU market.

In the U.S., the Food and Drug Administration (FDA) is moving forward with increased oversight of Laboratory Developed Tests (LDTs), which will now be subject to the same regulatory requirements as commercial IVDs, including premarket review and post-market surveillance. Plus, the FDA's Quality Management System Regulation (QMSR), aligning U.S. standards with the international ISO 13485, has a compliance deadline of February 2, 2026, requiring substantial internal process overhauls in 2025. This means you must budget for longer pre-market review cycles, adding months, defintely, to your time-to-market projections.

Here's the quick math on key near-term IVD compliance deadlines:

Intellectual property (IP) disputes in the highly competitive proteomics space, requiring significant legal defense spending.

The proteomics sector, with its high-value proprietary technology, is a hotbed for intellectual property (IP) litigation, particularly around novel protein analysis methods and proprietary reagents. This competitive dynamic means Seer, Inc. must maintain a substantial legal defense budget to protect its core P-Soma technology patents and defend against infringement claims from rivals.

The financial risk is material. While specific 2025 litigation figures for Seer, Inc. are confidential, industry benchmarks show that the cost of defending a high-stakes patent infringement case-where the financial exposure is over $25 million-can easily exceed $4 million through trial and appeal. Even a smaller, less complex case can cost a median of $700,000 just to see through to completion. This is a non-discretionary operating expense that can erode R&D capital.

To mitigate this, you need a proactive strategy, not just a reactive defense fund.

• Increase patent filing budget by 15% in FY 2025 to build a defensive patent moat.
• Budget for a minimum of $2.5 million in legal defense reserves for potential patent challenges.
• Conduct quarterly freedom-to-operate (FTO) analyses on new product features to preemptively identify infringement risks.

Evolving data privacy regulations (e.g., HIPAA, GDPR) governing the handling of patient-derived proteomic samples.

Handling patient-derived proteomic samples subjects Seer, Inc. to the most stringent global data privacy laws, particularly the U.S. Health Insurance Portability and Accountability Act (HIPAA) and the EU's General Data Protection Regulation (GDPR). Proteomic data, when linked to an individual, constitutes Protected Health Information (PHI) or sensitive personal data, mandating costly security and compliance infrastructure.

For a large-scale operation like a public company, initial HIPAA compliance setup costs can exceed $78,000, with ongoing yearly security and audit costs representing 30% to 50% of that initial investment. Non-compliance risks are existential: HIPAA violations carry an annual cap of up to $1.5 million for repeat offenses, and GDPR fines can reach up to €20 million or 4% of global annual revenue, whichever is higher. This is a crucial area for internal investment.

The primary compliance focus areas for proteomic data are:

• Explicit consent mechanisms for EU data subjects, adhering to GDPR's high standard.
• Data encryption both at rest and in transit, a HIPAA Security Rule requirement.
• Appointment of a Data Protection Officer (DPO) for GDPR compliance oversight.

Compliance costs related to international trade and export controls for dual-use research technologies.

The U.S. Bureau of Industry and Security (BIS) has significantly tightened export controls on advanced biotechnology tools in 2025, classifying them as dual-use research technologies-equipment that has both commercial and potential military applications. Specifically, an Interim Final Rule effective January 16, 2025, places new controls on certain liquid chromatography mass spectrometers (LC/MS) 'specially designed' for top-down proteomic analysis.

These instruments, which are central to the proteomics field, are now classified under new Export Control Classification Numbers (ECCNs) 3A069 and 3E069. This means licenses are now required for exports to many destinations, with a 'presumption of denial' for high-risk countries. The cost here is twofold: a direct increase in compliance overhead (licensing fees, enhanced due diligence, denied party screening systems) and a loss of market opportunity due to restricted access to key foreign research markets. For the average affected U.S. supplier, export controls can result in a loss of market capitalization estimated at $857 million. This regulatory shift requires an immediate, high-priority review of all international sales and distribution channels.

Seer, Inc. (SEER) - PESTLE Analysis: Environmental factors

Customer demand for sustainable lab operations, pressuring Seer to reduce energy and waste footprint of its instruments and consumables.

The demand for green lab practices from major research institutions and pharmaceutical clients is a direct pressure point for Seer. The life sciences sector is notoriously energy-intensive, consuming more energy per square foot than commercial buildings or hospitals, making efficiency a critical concern for customers.

You need to recognize that your customers are already moving: an Agilent report showed that 82 percent of labs surveyed have adopted sustainability initiatives, with top priorities being reducing water and energy consumption and improving waste management. Your Proteograph Product Suite, which relies on consumables and instrumentation, is now under scrutiny for its lifecycle environmental impact. Given Seer's expected full year 2025 revenue of $17 million to $18 million, demonstrating product sustainability is a clear opportunity to differentiate and secure contracts with large, ESG-focused clients.

This isn't a future problem; it's a 2025 purchasing requirement.

Supply chain scrutiny regarding the ethical sourcing of chemicals and materials used in manufacturing.

Scrutiny on the supply chain's ethical and environmental footprint is intensifying in 2025, especially for companies dealing with chemicals and advanced materials like the proprietary engineered nanoparticles (NP) in Seer's Proteograph technology. The chemical industry is seeing a major push toward ESG compliance and supplier collaboration.

The core risk here is a growing gap between corporate sustainability ambitions and actual supplier performance, which can lead to reputational harm. For Seer, with its focus on high-tech consumables, this means rigorously screening suppliers for compliance with fair labor standards and anti-corruption policies, which is now mandatory for many international suppliers. Without public disclosure of a formal supplier code of conduct or audit program, Seer faces a higher due diligence burden compared to peers with established transparency frameworks.

Increased reporting requirements on Scope 1, 2, and 3 emissions for publicly traded life science companies.

The regulatory and investor pressure for comprehensive Greenhouse Gas (GHG) reporting is escalating rapidly. A 2025 report showed that 79% of surveyed companies now report on all three Scopes (1, 2, and 3), a significant 27-point year-on-year increase. For a life science company like Seer, the vast majority of your carbon impact lies outside your direct operations, specifically in your value chain, categorized as Scope 3 emissions.

PwC estimates that between 65% and 95% of most companies' carbon impact falls under Scope 3. The lack of public disclosure on Seer's Scope 1 (direct), Scope 2 (purchased energy), and especially Scope 3 (value chain) emissions is a material risk. This non-disclosure contrasts sharply with industry trends, where 100% of chemical sector companies (a key supplier category) disclose Scope 1 and 2 data. The market will soon penalize this lack of transparency.

Here's the quick math on the reporting imperative:

Risk of operational disruption from extreme weather events impacting manufacturing or key supplier sites.

Extreme weather events are no longer 'black swan' events; they are regular stress tests for global supply chains. Global economic losses from natural catastrophes rose to $162 billion in the first half of 2025, up from $156 billion the previous year. This affects the life science sector directly, which relies on complex, often single-site, manufacturing for critical components.

The vulnerability is clear: nearly two-thirds (62.8%) of all US drug production facilities were located in counties that had at least one disaster declaration between 2019 and 2024. A single event, like the 2024 Hurricane Helene damaging a Baxter facility, caused a nationwide shortage of intravenous fluids. Seer's manufacturing and key suppliers for its Proteograph instruments and consumable kits are exposed to similar regional risks. The reliance on a just-in-time inventory model, common in the sector, amplifies this risk, potentially disrupting the supply of essential chemicals and materials and stalling sales, which are projected to be between $17 million and $18 million for the full year 2025. You defintely need to map your tier-1 and tier-2 supplier locations against FEMA disaster zones.

Concrete action: Finance should draft a 13-week cash view by Friday that models a 30-day disruption to the top three consumable suppliers.